Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
Date:5/5/2009

ollment target and a total of 401 patients were enrolled in the SPEAR (Study of Picoplatin Efficacy After Relapse) trial. The global, pivotal Phase 3 SPEAR trial is evaluating the efficacy and safety of picoplatin in patients with refractory or progressive small cell lung cancer (SCLC) who have failed prior platinum-containing first-line chemotherapy regiments or who have progressed within six months of first-line therapy. Patients were enrolled at more than 100 clinical trial sites in 16 countries in Europe, South America and Asia.
  • In May, the Company announced that the independent Data Monitoring Committee, after review of available information regarding the efficacy, safety and quality of trial conduct, recommends that the SPEAR trial continue.
  • Colorectal Cancer
    • In April, final data from a Phase 1 dose-escalation study of picoplatin in patients with metastatic colorectal cancer (CRC) was presented at the American Association for Cancer Research's (AACR) 100th Annual Meeting 2009. Results demonstrated that picoplatin can be safely administered in combination with 5-fluorouracil and leucovorin in the FOLPI regimen as a first-line treatment for CRC. Based on the clinical activity and promising safety data observed in the Phase 1 study, Poniard initiated a randomized, controlled, proof-of-concept Phase 2 trial in November 2007 to evaluate picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed in May 2008.
  • Oral Picoplatin
    • In April, final data from a Phase 1 clinical study of an oral formulation of picoplatin in patients with solid tumors was also presented at the AACR Annual Meeting. Results showed that the bioavailability of oral picoplatin is nearly 100 percent at doses of 50 mg and 100 mg, indicating sufficient bioavailability
      '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
    2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
    3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
    5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
    6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
    7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
    8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
    9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
    10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
    11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
    (Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
    (Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
    Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
    ... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
    ... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
    Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
    (Date:8/31/2015)... ... August 31, 2015 , ... Thermi, a ... is proud to announce South Korea’s Ministry of Food and Drug Safety ... most sought-after radio frequency thermotherapy technology available in United States, South Korea, Thailand, ...
    (Date:8/30/2015)... ... August 30, 2015 , ... ProTrailer Party is a new and exciting ... 30 styled and detailed presets, allowing FCPX users to immerse the audience into ... will help film makers save time while adding professional titles to every project. , ...
    (Date:8/30/2015)... ... 2015 , ... Intellitec Solutions, based in Wilmington, DE, will ... & 6th in San Antonio, TX. Dedicated to bringing long term and post-acute ... over the country come to share the latest and greatest in healthcare technologies, ...
    (Date:8/30/2015)... ... 30, 2015 , ... Lizzie’s Lice Pickers , a company that offers ... is currently offering lice head checks for just $10, which is a significant discount ... discount on their lice treatment products. “With kids returning to school, it is very ...
    (Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and skin ... skin care experience having spent the last 25 years working in operations, purchasing ...
    Breaking Medicine News(10 mins):Health News:Thermi Heats Up South Korea Announcing Global Expansion with NewRegulatory Approvals for ThermiRF™ 2Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
    ... 21 Meridian International,Center today announced that its ... M.D. will lead Meridian,s new Global Health,Program. The ... of Meridian,s,programs that include world affairs public briefings ... and arts and,cultural activities., "Today, 79% of ...
    ... SinoFresh HealthCare,Inc. (OTC Bulletin Board: SFSH), a ... today announced that the company,s CEO,Charles Fust, is ... Show., The interview gives viewers an overview ... latest press release., To ...
    ... It means different things to youngsters, so sex ed ... THURSDAY, Aug. 21 (HealthDay News) -- One reason why ... activity is because abstinence can mean different things to ... University of Washington study. , Teens, attitudes and intentions ...
    ... vaccination leading to increase, CDC report says , , THURSDAY, ... vaccinate children seems to be behind the highest rate ... Thursday. , Between Jan. 1 and July 31 of ... the United States, many of them among children whose ...
    ... League Baseball World Series, CHICAGO, Aug. 20 ... the winner of its annual slogan contest today,and ... coaches and parents,about tobacco addiction and the health ... tobacco. This year,s slogan contest winner is,Joe Reck, ...
    ... recently enacted Medicare Improvement Law immediately affects the operations ... ... nationwide, PORTLAND, Ore., Aug. 20 ... 6331, creating new legislation,protecting Medicare beneficiaries, they also established stricter,requirements for ...
    Cached Medicine News:Health News:Former U.S. Assistant Surgeon General, Dr. Susan Blumenthal, to Lead Meridian International Center's Global Health Program 2Health News:[video] Charles Fust, CEO of SinoFresh HealthCare, Inc. Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.net's 3-Minute Press Show 2Health News:Abstinence-Only Programs Fall Short of Teens' Needs 2Health News:Measles Cases Highest Since 1996 2Health News:Measles Cases Highest Since 1996 3Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2
    Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
    Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
    2 mm tip....
    4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
    Medicine Products: